Memorial Sloan-Kettering Cancer Center researchers have developed a transferrin-based PET imaging agent that could help diagnose prostate cancer with greater sensitivity than 18F-labeled fluorodeoxyglucose. It also can detect a precancerous prostate condition that is not otherwise amenable to imaging.